NPCE
NeuroPace Inc

328
Mkt Cap
$564.23M
Volume
54,742.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-22.48
NPCE Fundamentals
Price
$16.40
Prev Close
$16.94
Open
$16.38
50D MA
$15.52
Beta
1.19
Avg. Volume
206,940.32
EPS (Annual)
-$0.9318
P/B
30.44
Rev/Employee
$434,271.74
Loading...
Loading...
News
all
press releases
NeuroPace, Inc. (NASDAQ:NPCE) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are currently covering the firm, Marketbeat...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited results for the fourth quarter ended...
Business Wire·7d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Sees Strong Trading Volume - Here's Why
NeuroPace (NASDAQ:NPCE) Sees Unusually-High Trading Volume - Should You Buy...
MarketBeat·14d ago
News Placeholder
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual...
Business Wire·20d ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, Marketbeat...
MarketBeat·29d ago
News Placeholder
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS System Indication for Idiopathic Generalized Epilepsy
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a Premarket Approval Supplement (PMA-S...
Business Wire·1mo ago
News Placeholder
UBS Group Raises NeuroPace (NASDAQ:NPCE) Price Target to $22.00
UBS Group upped their target price on shares of NeuroPace from $18.00 to $22.00 and gave the stock a "buy" rating in a report on Tuesday...
MarketBeat·1mo ago
News Placeholder
JPMorgan Chase & Co. Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price
JPMorgan Chase & Co. lifted their price target on shares of NeuroPace from $18.00 to $20.00 and gave the company an "overweight" rating in a research note on Wednesday...
MarketBeat·1mo ago
News Placeholder
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the American Epilepsy Society (AES) meeting of...
Business Wire·1mo ago
News Placeholder
NeuroPace, Inc. $NPCE Shares Acquired by Divisadero Street Capital Management LP
Divisadero Street Capital Management LP lifted its position in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 529.2% during the 2nd quarter, according to the company in its most recent 13F...
MarketBeat·1mo ago
<
1
2
...
>

Latest NPCE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.